Robert Stewart - Allergan Plc President
President
Mr. Robert A. Stewart is no longer Chief Operating Officer of Allergan Plc., Prior to his current appointment, Mr. Stewart served as President, Generics and Global Operations from March 2015 to May 2016 Chief Operating Officer from July 2014 to March 2015 and President, Global Operations, from August 2010 to July 2014. He joined the Company in November 2009 as Senior Vice President, Global Operations. Prior to joining Watson, Mr. Stewart held various positions with Abbott Laboratories, Inc. from 2001 until 2009 where he most recently served as Divisional Vice President, Global Supply Chain, Quality Assurance and prior to this position served as Divisional Vice President for U.S.Puerto Rico and Latin America Plant Operations. Prior to joining Abbott Laboratories, Inc., he worked for Knoll Pharmaceutical Company from 1995 to 2001 and Hoffman LaRoche Inc
Age | 49 |
Phone | 862 261 7000 |
Web | http://www.allergan.com |
Robert Stewart Latest Insider Activity
Tracking and analyzing the buying and selling activities of Robert Stewart against Allergan Plc stock is an integral part of due diligence when investing in Allergan Plc. Robert Stewart insider activity provides valuable insight into whether Allergan Plc is net buyers or sellers over its current business cycle. Note, Allergan Plc insiders must abide by specific rules, including filing SEC forms every time they buy or sell Allergan Plc'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Robert Stewart over six months ago P10 exotic insider transaction detected |
Allergan Plc Management Efficiency
The company has Return on Asset of (0.0564) % which means that on every $100 spent on assets, it lost $0.0564. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0913) %, meaning that it generated no profit with money invested by stockholders. Allergan Plc's management efficiency ratios could be used to measure how well Allergan Plc manages its routine affairs as well as how well it operates its assets and liabilities.The company has 23.08 B in debt with debt to equity (D/E) ratio of 39.4, demonstrating that the company may be unable to create cash to meet all of its financial commitments. Allergan Plc has a current ratio of 0.98, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Debt can assist Allergan Plc until it has trouble settling it off, either with new capital or with free cash flow. So, Allergan Plc's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Allergan Plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Allergan to invest in growth at high rates of return. When we think about Allergan Plc's use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | PRESIDENT Age | ||
Nathaniel Colson | MGIC Investment Corp | 40 | |
James Hughes | MGIC Investment Corp | 61 | |
Jeffrey Long | Enersys | 63 | |
Paula Maggio | MGIC Investment Corp | 55 | |
Salvatore Miosi | MGIC Investment Corp | 56 | |
Colin Maguire | PennantPark Investment | N/A | |
Thomas ONeill | Enersys | N/A | |
Didier Papadopoulos | Joby Aviation | 49 | |
Sean Kapur | PennantPark Investment | N/A | |
Robert Candelmo | MGIC Investment Corp | 60 | |
Chad Uplinger | Enersys | N/A | |
Shawn OConnell | Enersys | 51 | |
Gregory Chi | MGIC Investment Corp | 57 | |
Andrea Funk | Enersys | 53 | |
Bonny Simi | Joby Aviation | 62 | |
Michael Schmidtlein | Enersys | 59 | |
Andrew Zogby | Enersys | 63 | |
Myles Jones | Enersys | 50 | |
Holger Aschke | Enersys | 49 | |
Stephen Mackey | MGIC Investment Corp | 57 |
Management Performance
Return On Equity | -0.0913 | |||
Return On Asset | -0.0564 |
Allergan Plc Leadership Team
Elected by the shareholders, the Allergan Plc's board of directors comprises two types of representatives: Allergan Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Allergan. The board's role is to monitor Allergan Plc's management team and ensure that shareholders' interests are well served. Allergan Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Allergan Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
Matthew Walsh, Chief Financial Officer, Executive Vice President | ||
Robert Bailey, Chief Legal Officer and Corporate Secretary | ||
Robert Stewart, Executive VP and President of Generic and Global Operations | ||
Ronald Taylor, Independent Director | ||
Adriane Brown, Independent Director | ||
William Meury, Executive Vice President, Chief Commercial Officer | ||
Brenton Saunders, Chairman of the Board, President, Chief Executive Officer | ||
Wayne Swanton, Executive Vice President - Global Operations | ||
Robert Hugin, Independent Director | ||
Nicholson, Chief R&D Officer | ||
Christopher Bodine, Independent Director | ||
Karen Ling, Chief Human Resource Officer, Executive Vice President | ||
Michael Gallagher, Lead Independent Director | ||
Paul Bisaro, Executive Chairman | ||
Thomas Freyman, Independent Director | ||
Catherine Klema, Lead Independent Director | ||
James DArecca, Chief Accounting Officer | ||
Christopher Coughlin, Lead Independent Director | ||
Nesli Basgoz, Independent Director | ||
Philippe Schaison, Executive Vice President and President Allergan Medical | ||
Maria Hilado, CFO and Executive VP | ||
Joseph Boccuzi, Independent Director | ||
Patrick OSullivan, Independent Director | ||
Fred Weiss, Independent Director | ||
A Bailey, Executive Vice President, Chief Legal Officer and Corporate Secretary | ||
Alex Kelly, Chief Communications Officer | ||
CDavid Nicholson, Executive Vice President, Chief R&D Officer | ||
Carol Davidson, Independent Director | ||
Michael Greenberg, Independent Director | ||
Ron Taylor, Independent Director | ||
Jonathon Kellerman, Executive Vice President Chief Compliance Officer | ||
Paul Navarre, Executive Vice President and President International Brands | ||
James Bloem, Independent Director | ||
Karina Calzadilla, IR Contact Officer | ||
Peter McDonnell, Independent Director |
Allergan Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Allergan Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.0913 | |||
Return On Asset | -0.0564 | |||
Profit Margin | (0) % | |||
Operating Margin | 6.84 % | |||
Current Valuation | 81.41 B | |||
Shares Outstanding | 328.1 M | |||
Shares Owned By Insiders | 0.16 % | |||
Shares Owned By Institutions | 98.25 % | |||
Number Of Shares Shorted | 15.01 M | |||
Price To Earning | 24.00 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Allergan Plc in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Allergan Plc's short interest history, or implied volatility extrapolated from Allergan Plc options trading.
Pair Trading with Allergan Plc
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allergan Plc position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allergan Plc will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Charles Schwab could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Charles Schwab when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Charles Schwab - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Charles Schwab Corp to buy it.
The correlation of Charles Schwab is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Charles Schwab moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Charles Schwab Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Charles Schwab can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Allergan Plc information on this page should be used as a complementary analysis to other Allergan Plc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in Allergan Stock
If you are still planning to invest in Allergan Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Allergan Plc's history and understand the potential risks before investing.
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |